Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Long-term, Open-label Extension Study of the Safety and Tolerability of RGH-188 (Cariprazine) in Patients With Schizophrenia

NCT00839852 is registered in ClinicalTrials.gov with Forest Laboratories as lead sponsor.

NCT NCT00839852
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00839852 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Long-term, Open-label Extension Study of the Safety and Tolerability of RGH-188 (Cariprazine) in Patients With Schizophrenia
Lead sponsor
Forest Laboratories
Phase
Phase 2
Overall status
Completed
Start date
May 31, 2009
Completion date
August 31, 2010
Enrollment
97 (actual)
Sites
65

Conditions

As the registry lists them; a condition with its own page is linked.

schizophrenia